Literature DB >> 21962754

Multiple system atrophy: a clinical and neuropathological perspective.

Kiren Ubhi1, Phillip Low, Eliezer Masliah.   

Abstract

Multiple system atrophy (MSA) is a neurodegenerative disease involving motor abnormalities that include akinesia, rigidity and postural instability. While improved diagnostic criteria have aided the accurate diagnosis of MSA, our understanding of the neuropathological aspects underlying MSA was bolstered by the identification of α-synuclein (α-syn) as the primary constituent of the abnormal protein aggregates observed in the brains of MSA patients. The generation of transgenic animal models of MSA coupled with an increasing understanding of the biochemical structure and function of α-syn has highlighted a number of key pathological pathways thought to underlie the neurodegeneration observed in MSA. This review summarizes key findings in the field, discusses current areas of debate, and describes current experimental approaches towards disease-modifying therapies.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21962754      PMCID: PMC3200496          DOI: 10.1016/j.tins.2011.08.003

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  116 in total

Review 1.  Oxidative stress and nitration in neurodegeneration: cause, effect, or association?

Authors:  Harry Ischiropoulos; Joseph S Beckman
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

2.  Striatal transplantation in a rodent model of multiple system atrophy: effects on L-Dopa response.

Authors:  Martin Köllensperger; Nadia Stefanova; Anton Pallua; Zoe Puschban; Georg Dechant; Monika Hainzer; Markus Reindl; Werner Poewe; Guido Nikkhah; Gregor K Wenning
Journal:  J Neurosci Res       Date:  2009-05-15       Impact factor: 4.164

3.  Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy.

Authors:  J G Graham; D R Oppenheimer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1969-02       Impact factor: 10.154

4.  Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes.

Authors:  Philipp J Kahle; Manuela Neumann; Laurence Ozmen; Veronika Muller; Helmut Jacobsen; Will Spooren; Babette Fuss; Barbara Mallon; Wendy B Macklin; Hideo Fujiwara; Masato Hasegawa; Takeshi Iwatsubo; Hans A Kretzschmar; Christian Haass
Journal:  EMBO Rep       Date:  2002-05-24       Impact factor: 8.807

5.  Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome).

Authors:  M I Papp; J E Kahn; P L Lantos
Journal:  J Neurol Sci       Date:  1989-12       Impact factor: 3.181

6.  Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy.

Authors:  Nadia Stefanova; Markus Reindl; Manuela Neumann; Christian Haass; Werner Poewe; Philipp J Kahle; Gregor K Wenning
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

7.  Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.

Authors:  F Blandini; M T Armentero; R Fancellu; E Blaugrund; G Nappi
Journal:  Exp Neurol       Date:  2004-06       Impact factor: 5.330

8.  The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.

Authors:  Oleg S Gorbatyuk; Shoudong Li; Layla F Sullivan; Weijun Chen; Galina Kondrikova; Fredric P Manfredsson; Ronald J Mandel; Nicholas Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-04       Impact factor: 11.205

9.  Survival in multiple system atrophy.

Authors:  Anette Schrag; Gregor K Wenning; Niall Quinn; Yoav Ben-Shlomo
Journal:  Mov Disord       Date:  2008-01-30       Impact factor: 10.338

10.  Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor.

Authors:  Alastair Wilkins; Henry Majed; Robert Layfield; Alastair Compston; Siddharthan Chandran
Journal:  J Neurosci       Date:  2003-06-15       Impact factor: 6.167

View more
  70 in total

1.  Neuronal to oligodendroglial α-synuclein redistribution in a double transgenic model of multiple system atrophy.

Authors:  Edward Rockenstein; Kiren Ubhi; Chandra Inglis; Michael Mante; Christina Patrick; Anthony Adame; Eliezer Masliah
Journal:  Neuroreport       Date:  2012-03-07       Impact factor: 1.837

2.  Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology.

Authors:  Shunsuke Koga; Maiko Ono; Naruhiko Sahara; Makoto Higuchi; Dennis W Dickson
Journal:  Mov Disord       Date:  2017-04-25       Impact factor: 10.338

3.  Uric acid is associated with the prevalence but not disease progression of multiple system atrophy in Chinese population.

Authors:  Bei Cao; Xiaoyan Guo; Ke Chen; Wei Song; Rui Huang; Qian-Qian Wei; Bi Zhao; Hui-Fang Shang
Journal:  J Neurol       Date:  2013-06-26       Impact factor: 4.849

4.  Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial.

Authors:  Phillip A Low; David Robertson; Sid Gilman; Horacio Kaufmann; Wolfgang Singer; Italo Biaggioni; Roy Freeman; Susan Perlman; Robert A Hauser; William Cheshire; Stephanie Lessig; Steven Vernino; Jay Mandrekar; William D Dupont; Thomas Chelimsky; Wendy R Galpern
Journal:  Lancet Neurol       Date:  2014-02-05       Impact factor: 44.182

5.  FTY720-Mitoxy reduces toxicity associated with MSA-like α-synuclein and oxidative stress by increasing trophic factor expression and myelin protein in OLN-93 oligodendroglia cell cultures.

Authors:  Javier Vargas-Medrano; Ismael Segura-Ulate; Barbara Yang; Ramesh Chinnasamy; Jeffrey B Arterburn; Ruth G Perez
Journal:  Neuropharmacology       Date:  2019-07-07       Impact factor: 5.250

Review 6.  Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy.

Authors:  E Valera; G Monzio Compagnoni; E Masliah
Journal:  Neuropathol Appl Neurobiol       Date:  2016-02       Impact factor: 8.090

7.  Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction.

Authors:  Zhenwei Yu; Min Shi; Tessandra Stewart; Pierre-Olivier Fernagut; Yang Huang; Chen Tian; Benjamin Dehay; Anzari Atik; Dishun Yang; Francesca De Giorgi; François Ichas; Marie-Hélène Canron; Roberto Ceravolo; Daniela Frosini; Han-Joon Kim; Tao Feng; Wassilios G Meissner; Jing Zhang
Journal:  Brain       Date:  2020-06-01       Impact factor: 13.501

Review 8.  Optimizing clinical trial design for multiple system atrophy: lessons from the rifampicin study.

Authors:  Wolfgang Singer; Phillip A Low
Journal:  Clin Auton Res       Date:  2015-03-13       Impact factor: 4.435

9.  Prodegenerative IκBα expression in oligodendroglial α-synuclein models of multiple system atrophy.

Authors:  Christine L Kragh; Amanda M Gysbers; Edward Rockenstein; Karen Murphy; Glenda M Halliday; Eliezer Masliah; Poul Henning Jensen
Journal:  Neurobiol Dis       Date:  2013-12-17       Impact factor: 5.996

10.  Sleep dysfunction in multiple system atrophy.

Authors:  Luigi Ferini-Strambi; Sara Marelli
Journal:  Curr Treat Options Neurol       Date:  2012-10       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.